Completed PHASE1 INTERVENTIONAL 5-arm NCT00919490

A Study of Single Dose of ABT-333 in Healthy Male Adults

A Double-blind, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Dose of ABT-333

Sponsor: Abbott

Conditions HCV Infections

Interventions ABT-333 Placebo

Updated 5 times since 2017 Last updated: Oct 22, 2010 Started: Jun 30, 2009 Primary completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00919490, this PHASE1 trial focuses on HCV Infections and remains completed. Sponsored by Abbott, it has been updated 5 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Abbott Japan Co.,Ltd

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kagoshima, Japan